Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis
Posted innews Oncology

Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis

A patient‑level and trial‑level meta‑analysis of nine RCTs (5,114 patients) shows that adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves pathologic complete response and event‑free survival in triple‑negative breast cancer and PD‑L1+ HR+/ERBB2‑ tumors, with a manageable immune toxicity profile.